AU2002310904B2 - Dihydroimidazo[4,5-e]indole and 7H-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands - Google Patents

Dihydroimidazo[4,5-e]indole and 7H-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands Download PDF

Info

Publication number
AU2002310904B2
AU2002310904B2 AU2002310904A AU2002310904A AU2002310904B2 AU 2002310904 B2 AU2002310904 B2 AU 2002310904B2 AU 2002310904 A AU2002310904 A AU 2002310904A AU 2002310904 A AU2002310904 A AU 2002310904A AU 2002310904 B2 AU2002310904 B2 AU 2002310904B2
Authority
AU
Australia
Prior art keywords
formula
compound
solvate
physiologically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002310904A
Other languages
English (en)
Other versions
AU2002310904A1 (en
Inventor
Henning Bottcher
Joachim Leibrock
Kai Schiemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2002310904A1 publication Critical patent/AU2002310904A1/en
Application granted granted Critical
Publication of AU2002310904B2 publication Critical patent/AU2002310904B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2002310904A 2001-04-30 2002-03-30 Dihydroimidazo[4,5-e]indole and 7H-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands Ceased AU2002310904B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10121215A DE10121215A1 (de) 2001-04-30 2001-04-30 Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
DE10121215.1 2001-04-30
PCT/EP2002/003582 WO2002088143A2 (en) 2001-04-30 2002-03-30 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands

Publications (2)

Publication Number Publication Date
AU2002310904A1 AU2002310904A1 (en) 2003-04-17
AU2002310904B2 true AU2002310904B2 (en) 2008-01-10

Family

ID=7683301

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002310904A Ceased AU2002310904B2 (en) 2001-04-30 2002-03-30 Dihydroimidazo[4,5-e]indole and 7H-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands

Country Status (13)

Country Link
US (1) US7279496B2 (https=)
EP (1) EP1383774B1 (https=)
JP (1) JP4593879B2 (https=)
AR (1) AR033624A1 (https=)
AT (1) ATE394404T1 (https=)
AU (1) AU2002310904B2 (https=)
CA (1) CA2445834C (https=)
CZ (1) CZ20033195A3 (https=)
DE (2) DE10121215A1 (https=)
ES (1) ES2303857T3 (https=)
HU (1) HUP0304046A2 (https=)
SK (1) SK14472003A3 (https=)
WO (1) WO2002088143A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1656093A (zh) * 2002-05-30 2005-08-17 神经研究公司 3－取代的奎宁环及其用途
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
ZA200709038B (en) * 2005-04-13 2009-01-28 Neuraxon Inc Substituted indole compounds having nos inhibitory activity
US7897766B2 (en) * 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
CN101466709B (zh) * 2006-04-13 2013-03-20 轴突公司 具有nos抑制活性的1,5和3,6-取代的吲哚化合物
EA201000808A1 (ru) * 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
EP2219449A4 (en) * 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
WO2009062318A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
FR3165598A1 (fr) 2024-08-14 2026-02-20 Ultrawatt Élément d’habillage d’une paroi et kit comportant au moins un tel élément

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009565A1 (de) 1990-03-24 1991-09-26 Merck Patent Gmbh Indolderivate
ATE157977T1 (de) * 1992-10-13 1997-09-15 Warner Lambert Co Chinoxalinderivate als eaa antagonisten
US5843945A (en) 1993-05-13 1998-12-01 Neurosearch A/S AMPA antagonists and a method of treatment
WO1994026747A1 (en) 1993-05-13 1994-11-24 Neurosearch A/S Ampa antagonists and a method of treatment therewith
AU727608B2 (en) * 1995-10-03 2000-12-14 Scripps Research Institute, The CBI analogs of CC-1065 and the duocarmycins
US6147096A (en) * 1998-02-26 2000-11-14 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrrolobenzimidazoles for treating inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 59156-95-5 *

Also Published As

Publication number Publication date
JP4593879B2 (ja) 2010-12-08
HUP0304046A2 (hu) 2004-04-28
DE10121215A1 (de) 2002-10-31
DE60226428D1 (de) 2008-06-19
JP2004529936A (ja) 2004-09-30
EP1383774B1 (en) 2008-05-07
CZ20033195A3 (cs) 2004-02-18
EP1383774A2 (en) 2004-01-28
ATE394404T1 (de) 2008-05-15
SK14472003A3 (sk) 2004-04-06
US20040142935A1 (en) 2004-07-22
WO2002088143A2 (en) 2002-11-07
AR033624A1 (es) 2003-12-26
WO2002088143A3 (en) 2003-01-23
CA2445834C (en) 2011-06-28
ES2303857T3 (es) 2008-09-01
US7279496B2 (en) 2007-10-09
CA2445834A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
AU617785B2 (en) Spirocyclic compounds incorporating five-membered rings with two heteroatoms
AU2003272316A1 (en) Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans
CA3137328A1 (en) Bisheterocyclic carbonyl substituted dihydropyrazole compound as rip1 kinase inhibitor
AU2002310904B2 (en) Dihydroimidazo[4,5-e]indole and 7H-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
JP2010524887A (ja) 抗菌剤としての含窒素三環式複素環化合物
US7741343B2 (en) 6H-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
EP3166924A1 (en) Aromatic heterocyclic derivatives and pharmaceutical applications thereof
US8765779B2 (en) Tricyclic derivatives and their pharmaceutical use and compositions
EP3083588A1 (en) Aromatic heterocyclic compounds and their application in pharmaceuticals
AU2002310904A1 (en) Dihydroimidazo[4,5-e]indole and 7H-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
US9840482B2 (en) Sulfonamide derivatives and pharmaceutical applications thereof
AU2002257752A1 (en) 6H-OXAZOLO[4,5-E]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
EP2516446B1 (en) Substituted hexahydrochromeno[3,4-b]pyrroles with affinity for the serotonin receptor (5-ht) family
HK1174918B (en) Substituted hexahydrochromeno[3,4-b]pyrroles with affinity for the serotonin receptor (5-ht) family

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired